-
公开(公告)号：WO2007095784A1
公开(公告)日：2007-08-30
申请号：PCT/CN2006/000662
申请日：2006-04-13
Applicant: 中国科学院上海药物研究所 , 南京长澳医药科技有限公司 , 杨玉社 , 樊后兴 , 陈凯先 , 嵇汝运
IPC: C07D413/14 , A61K31/422 , A61P31/04
CPC classification number: C07D413/06
Abstract: The present invention provided a kind of triazolyl-containing oxazolidinone derivatives represented by the following formula (I), their pharmaceutically acceptable salts, preparation method and the uses for the manufacture of medicament for the treatment of infectious diseases, especially the infectious diseases caused by Multi-drug resistant bacteria. The triazolyl-containing oxazolidinone derivatives of the present application, or their pharmaceutically acceptable salts have excellent antibiotic activity and metabolic activity in vitro or in vivo, they can decrease the inhibitory activity of C-5 acetamido oxazolidinone derivatives to MAO-A, so that the clinical negative reactions of these medicaments are decreased.
-
公开(公告)号：WO2011147259A1
公开(公告)日：2011-12-01
申请号：PCT/CN2011/073961
申请日：2011-05-12
Applicant: 中国科学院上海药物研究所 , 南京长澳医药科技有限公司 , 杨玉社 , 辛启胜 , 樊后兴 , 郭彬 , 刘昕 , 何慧丽 , 李纬 , 李战
IPC: C07D498/04 , A61K31/424 , A61P31/04
CPC classification number: C07D498/04
-
公开(公告)号：WO2010028542A1
公开(公告)日：2010-03-18
申请号：PCT/CN2009/000979
申请日：2009-08-27
Applicant: 中国科学院上海药物研究所 , 南京长澳医药科技有限公司 , 杨玉社 , 姜智腾 , 付利强 , 蔡瞻 , 李战 , 晁阳 , 嵇汝运
IPC: C07F9/09 , C07D221/22 , C07D249/08 , A61K31/661 , A61K31/4196 , A61K31/403 , A61P31/00
CPC classification number: C07F9/117 , C07D249/14 , C07D451/04 , C07F9/12 , C07F9/65182 , C07F9/6561
-
公开(公告)号：WO2009140859A1
公开(公告)日：2009-11-26
申请号：PCT/CN2009/000542
申请日：2009-05-19
CPC classification number: A61K36/59 , A61K31/4375
-
Patent Agency Ranking
公开(公告)号：WO2008128431A1
公开(公告)日：2008-10-30
申请号：PCT/CN2008/000795
申请日：2008-04-17
IPC: C07D455/03 , A61K31/4375 , A61P25/00 , A61P25/18
CPC classification number: C07D455/03
Abstract: The invention relates to l-stepholidine (l-SPD) derivant described as general formula (I) and its producing method. Said l-SPD derivatives and pharmacological acceptable salts, crystalline hydrates, solvates thereof have a double pharmacological effects of dopamine receptor D1 agonistic-D2 antagonistic in global cerebra and have a good physicochemical property and oral bioavailability and can be used to prepare the medicine for treating human or animal nervous system diseases, especially for schizophrenosis and other dopamine receptor correlated nervous system diseases.
-
公开(公告)号：WO2010145206A1
公开(公告)日：2010-12-23
申请号：PCT/CN2010/000885
申请日：2010-06-17
Applicant: 中国科学院上海药物研究所 , 杨玉社 , 程建军 , 嵇汝运
IPC: C07D217/20 , C07D455/03 , A61K31/472 , A61P25/00
CPC classification number: C07D471/04 , C07D217/24
-
公开(公告)号：WO2008014661A1
公开(公告)日：2008-02-07
申请号：PCT/CN2007/001734
申请日：2007-05-29
IPC: C07D455/03 , A61K31/4375 , A61P25/00 , A61P25/18
CPC classification number: C07D455/03
Abstract: The present invention affords tetrahydroprotoberberine compounds listed as formula (I) and their pharmaceutically acceptable inorganic or organic salts, crystallized hydrates, solvates and medicinal compositions. In the formula (I), R 1 , R 2 , R 3 and R 4 represent H, lined or branched chain C 1-4 alkyl, cyclopropyl, cyclopropyl methyl, methoxyl methyl, methoxycarbonylmethyl, aryl, benzyl, allyl, or substituted aryl or benzyl. R 5 and R 6 represent H, halogen, OH, SH, NO 2 , NH 2 , substituted or non-substituted lined or branched C 1-4 alkyl. The configuration of C-14 is R, S or its racemate. The present invention also provides their preparation process and application in preparing medicine for treating neurological diseases, especially dopamine receptor related neurological diseases.
-
公开(公告)号：WO2007101371A1
公开(公告)日：2007-09-13
申请号：PCT/CN2006/000663
申请日：2006-04-13
Applicant: 中国科学院上海药物研究所 , 南京长澳医药科技有限公司 , 杨玉社 , 付晓钟 , 李战 , 嵇汝运
IPC: C07F9/6561 , A61K31/675 , A61P31/12
CPC classification number: C07F9/65616
Abstract: The invention provides purine bis-amino acid esters represented by formula (I), and pharmaceutically-acceptable inorganic or organic salts thereof, wherein R 1 is an amino group; R 2 is an amino-protected or free L-amino acid; n is 0 or 1; X is O or S. The invention also provides the preparation of such compounds and the use of such compounds as active substance in preparation of a medicament for the treatment of viral diseases. (I)
-
公开(公告)号：WO2007098644A1
公开(公告)日：2007-09-07
申请号：PCT/CN2006/000661
申请日：2006-04-13
Applicant: 中国科学院上海药物研究所 , 南京长澳医药科技有限公司 , 杨玉社 , 俞娟红 , 嵇汝运 , 陈凯先
IPC: C07D311/16 , C07D311/20 , A61K31/352 , A61K31/353 , A61P3/10
CPC classification number: C07D413/12 , C07D311/16 , C07D311/20
Abstract: 本发明提供式（I）所示的苯并吡喃类化合物及其药理上可接受的无机或有机盐，其中3，4位为单键或双键。当3，4位为单键时，4位碳原子的构型可以是R型或S型或是消旋体；R1表示氢原子或者含有取代基或不含取代基的C1-6烷基；R2表示氢原子、含有取代基或不含取代基的C1-6烷基、含有取代基或不含取代基的芳香环基或芳香杂环基；X代表CH2、O、S；n=2或3。本发明还提供该类化合物制备方法及包含该类化合物做为活性物质的用于治疗II型糖尿病及其并发症的药物组合物。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.027 seconds)
